This site uses cookies to improve your experience. To help us insure we adhere to various privacy regulations, please select your country/region of residence. If you do not select a country, we will assume you are from the United States. Select your Cookie Settings or view our Privacy Policy and Terms of Use.
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Used for the proper function of the website
Used for monitoring website traffic and interactions
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Strictly Necessary: Used for the proper function of the website
Performance/Analytics: Used for monitoring website traffic and interactions
Neuromodulation isn’t just about stimulating nerves; it’s about awakening hope and transforming lives—one patient at a time. In this episode, Blake Williams takes us on a wild journey through his career as a Field Clinical Engineer (FCE), shedding light on the incredible impact of neuromodulation on the lives of patients.
Traditionally, Medical Affairs has focused on cross-functional collaboration with commercial and R&D teams, medical communication, evidence generation, and dissemination. If you apply the right AI engines, you will get increasingly better insights. The goal is to have very targeted content for KOLs,” said GSK’s DeStefano. “A
Dr Boshoff is the ideal leader to propel Pfizer’s R&D engine forward…with a more focused strategy, driving the delivery of additional impactful breakthrough medicines with blockbuster potential,” stated Dr Albert Bourla , Chairman and Chief Executive Officer. Academy of MedicalSciences. “I
However, the Autumn Budget provides some relief via additional funding for the strained NHS, a welcome outcome considering for example, that “record numbers of cancer patients are having to wait longer than they should to begin their treatment”, explained Naser Turabi, Director of Evidence and Implementation at Cancer Research UK.
1 Particularly, CAR-T cell therapy, which uses a patient’s T-cells to fight cancer by altering them so they can find and destroy cancer cells, has emerged as a valuable option for many patients. 2 With this new indication, more patients will be able to access this innovative treatment.
Career success in MedTech is not just about climbing the corporate ladder; it’s about relentlessly advocating for patients, embracing change, and, above all, never giving up. with Fred Colen as he shares his transformation from an engineer to a MedTech executive. I am a person who has devoted his life to medical technology.
Schema markup is one of the levers that search engine optimization (SEO) specialists can leverage. Yet, it is surprisingly underutilized, making it an opportune way to increase your healthcare organization’s visibility on search engine results pages (SERPs). But where do you start?
All of these systems operate under the “master-slave” concept, which involves a surgeon sitting behind a console, away from the patient, who manipulates the mechanical arms of the robot via some kind of joystick-like device. More info can be found at the Biomed Israel website.
The first human trial done in Israel proved very successful (2017-2018, finalized during COVID), and published in the Red Journal , the official journal of the American Society for Radiation Oncology), involving many patients whose cancer recurred after treatment or whose options were exhausted. The rest of the patients had partial responses.
for patients with del(17p)/ TP53 mutation) and a favourable safety profile, including cardiac events, compared to ibrutinib ( ALPINE study ). It can be challenging to enrol patients given that, in areas of rapid advances in treatment like CLL, there are so many ongoing trials of new therapeutic approaches. for all-comers; HR=0.52
The early-stage venture financing firm Canaan Partners focuses on game-changing innovations in information, digital technologies, and the medicalsciences. Over the last 31 years, the firm has managed a highly diversified $5 billion fund that comprises some of the top names in technology and life sciences. Canaan Partners.
Well, yes, when patients got the migraine products that I sold, I knew for a fact that it would change their lives, but I didn’t get to see that directly. So you’re saying that, as a recruiter in that kind of space, it’s one thing to be helping people that are that removed from the patient impact. That is amazing.
This interaction enables the immune effector cells to target and kill cancer cells more effectively, significantly benefiting patients. These engineered T cells have shown remarkable efficacy in identifying and destroying multiple myeloma cells. How do you see the role of synthetic biology evolving in this landscape? Dr. William N.
We organize all of the trending information in your field so you don't have to. Join 8,000+ users and stay up to date on the latest articles your peers are reading.
You know about us, now we want to get to know you!
Let's personalize your content
Let's get even more personalized
We recognize your account from another site in our network, please click 'Send Email' below to continue with verifying your account and setting a password.
Let's personalize your content